Chronic airflow limitation in developing countries: burden and priorities.

Area of Science:

• Public Health
• Respiratory Medicine
• Global Health

Background:

• Respiratory diseases represent a significant global health burden, accounting for 12% of estimated DALYs lost globally in 2002.
• Chronic airflow limitation, primarily asthma and COPD, affects over 100 million individuals worldwide, with a disproportionate impact on developing countries.
• Existing international management guidelines (GINA for asthma, GOLD for COPD) have proven cost-effective in industrialized nations.

Purpose of the Study:

• To highlight the under-prioritization of respiratory diseases globally.
• To advocate for the adaptation of international asthma and COPD management guidelines for resource-limited settings.
• To emphasize the need for evidence-based decision-making by governments in addressing respiratory health.

Main Methods:

• Review of global health data on respiratory disease burden (DALYs).
• Analysis of existing international management guidelines (GINA, GOLD).
• Examination of WHO and International Union Against Tuberculosis and Lung Diseases initiatives (PAL, GARD, ADF).

Main Results:

• Respiratory diseases, despite their impact, have historically lacked priority.
• Adaptation of international guidelines using essential drugs is necessary for developing countries.
• Initiatives like WHO's PAL and GARD, and The Union's ADF aim to improve respiratory care and drug accessibility in developing regions.

Conclusions:

• Addressing the growing public health challenge of respiratory diseases in developing countries requires strategic prioritization and resource allocation.
• Adapting evidence-based guidelines and improving access to essential medicines are key interventions.
• Collaborative global efforts and targeted initiatives are vital for effective respiratory disease management worldwide.